<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793646</url>
  </required_header>
  <id_info>
    <org_study_id>24088719.4.0000.0068</org_study_id>
    <nct_id>NCT04793646</nct_id>
  </id_info>
  <brief_title>N-acetylcysteine for Primary Sjögren's Syndrome</brief_title>
  <acronym>NACSS</acronym>
  <official_title>Prospective Randomized, Double-blind Controlled Clinical Study of N-acetylcysteine for Treatment of Dryness Symptoms Due to Primary Sjogren's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      N-acetylcysteine (NAC) allows the elimination of reactive oxygen species (ROSs) and it has an&#xD;
      anti-inflammatory effect. For this reason, NAC has been used and researched for treatment of&#xD;
      several diseases, such as autoimmune diseases. In these diseases there are a process of&#xD;
      oxidative stress due to chronic inflammation, which promotes an imbalance between ROSs levels&#xD;
      and the cellular capacity to eliminate reactive intermediates and repair the resulting damage&#xD;
      through antioxidants. The imbalance between the production of free radicals from oxygen and&#xD;
      antioxidant species may also be involved in the pathogenesis of primary Sjögren's syndrome&#xD;
      (pSS). In fact, increased levels of oxidative stress markers were detected in biopsy samples&#xD;
      from minor salivary glands in these patients. Treatment of pSS is not well established and it&#xD;
      is also not able to modify the evolution of the disease, being often only symptomatic. In&#xD;
      addition, there is little data in the literature regarding the true efficacy of NAC in the&#xD;
      treatment of pSS and the few existing studies have evaluated heterogeneous populations&#xD;
      (including patients with other causes of sicca syndrome) and validated instruments to measure&#xD;
      the symptom index and disease activity were not use in these previous studies. Thus, the&#xD;
      present randomized double-blind clinical study aims to evaluate the efficacy of NAC in the&#xD;
      control of sicca syndrome symptoms in a homogeneous population of patients with pSS (not only&#xD;
      regarding the classification criteria, but also regarding the low rate of systemic disease&#xD;
      activity at study inclusion) through tests widely accepted in the literature. Additionally,&#xD;
      the investigators will study the possible role of NAC on oxidative stress in peripheral blood&#xD;
      and saliva of these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: This is a prospective, randomized, double-blind controlled study of&#xD;
      N-acetylcysteine (600 mg orally every 12 hours in the form of syrup) lasting 12 weeks for the&#xD;
      treatment of sicca syndrome symptoms due to pSS.&#xD;
&#xD;
      Patients: Sixty adult female patients (aged &gt;=18 years), with a well-established diagnosis of&#xD;
      pSS (2016 American College of Rheumatology (ACR)/ European League Against Rheumatism (EULAR)&#xD;
      and/or 2002 American-European Consensus classification criteria) and follow-up regularly at&#xD;
      the Sjögren Syndrome Outpatient Clinic of the Rheumatology Division of Hospital das Clínicas&#xD;
      da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP).&#xD;
&#xD;
      Sample size: There is only a controlled study of NAC for treatment of SS, which included a&#xD;
      heterogeneous population with a total of 26 patients and who observed superiority to placebo&#xD;
      in the sicca symptoms control. Based on this study, the investigators will work with a&#xD;
      convenience sample of 60 patients.&#xD;
&#xD;
      Clinical evaluation: It will be carried out at study inclusion, 4 weeks and 12 weeks through&#xD;
      clinical instruments widely accepted in the literature.&#xD;
&#xD;
      Laboratorial evaluation: ROs will also be assessed throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind controlled study of N-acetylcysteine for treatment of dryness symptoms due to primary Sjogren's syndrome</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinding of identical bottles of N-acetylcysteine and placebo syrup</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI)</measure>
    <time_frame>3 months</time_frame>
    <description>Comparative analysis of ESSPRI values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Xerostomia inventory</measure>
    <time_frame>3 months</time_frame>
    <description>Comparative analysis of xerostomia inventory values</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Sjögren Syndrome</condition>
  <condition>Sicca Syndrome</condition>
  <arm_group>
    <arm_group_label>N-acetylcysteine syrup</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Thirty pSS patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo syrup</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Thirty pSS patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine syrup</intervention_name>
    <description>N-acetylcysteine syrup 600 mg (15 mL) twice a day for 3 months</description>
    <arm_group_label>N-acetylcysteine syrup</arm_group_label>
    <other_name>N-acetylcysteine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo syrup</intervention_name>
    <description>Placebo syrup 15 mL twice a day for 3 months</description>
    <arm_group_label>Placebo syrup</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Agreement to participate in the study according to signed informed consent.&#xD;
&#xD;
          -  Filling the pSS classification criteria.&#xD;
&#xD;
          -  Absence of other autoimmune associates systemic diseases.&#xD;
&#xD;
          -  EULAR Sjögren Syndrome Disease Activity Index (ESSDAI) &lt;= 5.&#xD;
&#xD;
          -  Prednisone dose &lt; 20 mg/day at study inclusion.&#xD;
&#xD;
          -  Without pilocarpine or cevimeline use at study inclusion.&#xD;
&#xD;
          -  No use of N-acetylcysteine for at least 1 month before study inclusion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes, sarcoidosis, previous history of head and neck radiotherapy or iodine&#xD;
             therapy, positive serologies for HIV, hepatitis B and C, graft versus host disease,&#xD;
             IgG4 (immunoglobulin G4) related disease, and current use of antidepressants&#xD;
             tricyclics.&#xD;
&#xD;
          -  Current use of biological therapy.&#xD;
&#xD;
          -  Current smoking.&#xD;
&#xD;
          -  Alcoholism.&#xD;
&#xD;
          -  Liver cirrhosis and chronic kidney disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra Pasoto, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Division of Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. Review.</citation>
    <PMID>12006334</PMID>
  </reference>
  <reference>
    <citation>Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X; International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017 Jan;76(1):9-16. doi: 10.1136/annrheumdis-2016-210571. Epub 2016 Oct 26.</citation>
    <PMID>27789466</PMID>
  </reference>
  <reference>
    <citation>Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, Ramos-Casals M, Dörner T, Bombardieri S, Hachulla E, Brun JG, Kruize AA, Praprotnik S, Tomsic M, Gottenberg JE, Devauchelle V, Devita S, Vollenweider C, Mandl T, Tzioufas A, Carsons S, Saraux A, Sutcliffe N, Vitali C, Bowman SJ; EULAR Sjögren's Task Force. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011 Jun;70(6):968-72. doi: 10.1136/ard.2010.143743. Epub 2011 Feb 22.</citation>
    <PMID>21345815</PMID>
  </reference>
  <reference>
    <citation>Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, Gottenberg JE, Bootsma H, Mariette X, Vitali C; EULAR Sjögren's Task Force. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis. 2010 Jun;69(6):1103-9. doi: 10.1136/ard.2009.110619. Epub 2009 Jun 28. Erratum in: Ann Rheum Dis. 2011 May;70(5):880.</citation>
    <PMID>19561361</PMID>
  </reference>
  <reference>
    <citation>Walters MT, Rubin CE, Keightley SJ, Ward CD, Cawley MI. A double-blind, cross-over, study of oral N-acetylcysteine in Sjögren's syndrome. Scand J Rheumatol Suppl. 1986;61:253-8.</citation>
    <PMID>3296153</PMID>
  </reference>
  <reference>
    <citation>Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X. Primary Sjogren syndrome. BMJ. 2012 Jun 14;344:e3821. doi: 10.1136/bmj.e3821. Review.</citation>
    <PMID>22700787</PMID>
  </reference>
  <reference>
    <citation>Danilovic A, Lucon AM, Srougi M, Shimizu MH, Ianhez LE, Nahas WC, Seguro AC. Protective effect of N-acetylcysteine on early outcomes of deceased renal transplantation. Transplant Proc. 2011 Jun;43(5):1443-9. doi: 10.1016/j.transproceed.2011.02.020.</citation>
    <PMID>21693215</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

